The federal Project Grant award in the amount of $835,531 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University in conducting research on a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The award period runs from September 1, 2024 through August 31, 2027. The funding enables The Johns Hopkins University, a prominent research institution, to advance innovative biomedical research aimed at developing new therapeutic approaches to treat this challenging form of pancreatic cancer, which disproportionately impacts military service members and veterans.
Generated 4/1/25, 4:15 AM